Form 4: Director William J. Link Acquires TARS Pharmaceuticals Stock

Director William J. Link acquired 2,954 shares of Tarsus Pharmaceuticals common stock through the settlement of vested Restricted Stock Units.

Summary

• William J. Link, a Director at Tarsus Pharmaceuticals, Inc., acquired 2,954 shares of common stock on June 12, 2026.
• These shares were acquired through the settlement of vested Restricted Stock Units (RSUs).
• Each RSU represents a contingent right to receive one share of the company's common stock.
• The RSUs were originally granted on June 12, 2025, in connection with Mr. Link's service as a non-employee director.
• These RSUs vest in full on the one-year anniversary of the grant date, provided continuous service is maintained.
• Following this transaction, Mr. Link beneficially owns 119,286 shares of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, as it represents a routine settlement of vested equity compensation for a director rather than a new investment or sale decision.

Positives

• Director William J. Link's acquisition of shares indicates continued confidence in the company.
• The acquisition is a result of vested equity compensation, aligning director interests with shareholders.
• The number of shares acquired (2,954) is a modest increase to the director's holdings.

Future Outlook

No specific forward-looking statements or guidance were provided in this Form 4 filing, which primarily reports on a change in beneficial ownership.

Industry Context

StockSavvy.ai notes that Form 4 filings, like this one from Tarsus Pharmaceuticals, are standard disclosures for insider transactions. Such filings are closely watched by investors to gauge management's confidence and alignment with shareholder interests. The acquisition of shares through vested RSUs is a common practice in the pharmaceutical industry for director compensation.

Stakeholder Impact

• Shareholders: The acquisition by a director may be viewed positively, indicating confidence in the company's future prospects. It also represents the conversion of equity awards into actual shares.
• Management: Reinforces the alignment of director compensation with company performance.
• Employees: The use of RSUs as compensation is a common practice that can motivate and retain key personnel.

Key Dates

Keywords

Tarsus Pharmaceuticals, Form 4, SEC Filing, Director, Stock Acquisition, Restricted Stock Units, Equity Compensation, Beneficial Ownership